SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire & inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is trending strongly as its staking program sees significant adoption, with a substantial portion of tokens now locked, which the community views as a bullish indicator. Holders are rallying around its unique narrative as a 'pure belief asset' offering an alternative to traditional retirement plans, fueling widespread conviction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after securing FDA approval for NEREUS, marking the first new motion sickness treatment in decades. The community is highly focused on the drug's significant potential beyond motion sickness, particularly its ability to address nausea associated with GLP-1 weight loss medications, which could unlock a massive market. Investors are actively discussing whether the current valuation fully reflects this pivotal regulatory success and the company's broader pipeline.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology (AFJK) is currently experiencing extreme price swings and frequent trading halts, sparking active community discussion around its highly speculative nature as a "casino play." Many traders are focusing on its ultra-low float and high borrow rates, anticipating potential short squeezes, while others caution against a perceived "Chinese mafia pump" pattern often seen in similar volatile Chinese IPOs.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is generating significant buzz in the trading community, largely driven by its exceptionally low float and high insider ownership. Many view it as the next potential 'squeeze' play, drawing strong comparisons to recent low-float SPACs like AFJK and ASPC which saw substantial upward movement. This unique structural setup fuels active discussion about its potential for rapid price action.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing high volatility as investors await an overdue FDA decision on Relacorilant for Cushing's syndrome, a key PDUFA date that passed without official news. This has ignited intense community debate, with some highlighting strong GRACE trial data and the broader pipeline, while others express concern that the delay may indicate a Complete Response Letter amidst notable trading volume and market speculation.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid analyst caution on its revenue outlook, largely attributed to crypto market weakness. Simultaneously, its holiday "free gift" giveaways are sparking considerable community debate, with users expressing both appreciation for small crypto rewards and frustration over app glitches. Conversations also revolve around its sensitivity to Bitcoin's price and its future as a broad fintech platform.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

ProShares Short Bitcoin Strategy ETF ($BITI) is a focal point of market discussion as bearish sentiment on Bitcoin gains traction, with many anticipating a significant cryptocurrency pullback. The community is actively debating using inverse ETFs like BITI to either capitalize on or hedge against a potential Bitcoin correction, citing concerns over its speculative nature and "bubble" warnings from prominent investors. This reflects a prevailing view among some that Bitcoin's recent rally faces considerable downside risk.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

JFrog is seeing increased conversation after its recent strong quarterly performance, which showcased significant cloud growth and spurred multiple analyst upgrades. The community is actively discussing its pivotal role in secure AI model delivery and DevSecOps, alongside fresh institutional interest, positioning the software leader for continued momentum within the thriving tech sector.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending following an eight-figure contract award to provide spacecraft docking systems for The Exploration Company's European Nyx capsule. This news, coupled with the company's significant short interest and its strategic position in the burgeoning space infrastructure and defense sectors, is fueling community speculation about a potential short squeeze and a substantial revaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scilex (NASDAQ:SCLX) Stock Price Down 3% - Time to Sell?

Scilex (NASDAQ:SCLX) Shares Down 3% - Time to Sell...

Scilex (NASDAQ:SCLX) Stock Price Down 1.3% - Time to Sell?

Scilex (NASDAQ:SCLX) Shares Down 1.3% - What's Next...

<ul class="summary-bullets"><li>The first tranche in September 2025 was $8 million in Bitcoin.</li><li>The second tranche of $141.93 million brings the total investment to $150 million.</li><li>Datavault said the funds will boost digital asset reserves, supercomputing, platform growth, and new revenue streams.</li></ul>Datavault AI (DVLT) announced on Wednesday that it has closed the second tranche of a strategic Bitcoin (BTC)-backed investment from Scilex (SCLX), securing capital to expand its digital asset reserves.In this deal, Scilex used 1,237.6 Bitcoin (BTC) to receive a pre-funded warrant that can be converted into roughly 264 million Datavault shares.&nbsp;In total, Scilex is expected to receive approximately 278.9 million Datavault shares, including 15 million in common stock from the first tranche of investment.The first tranche of the investment, completed in September 2025, was also made in Bitcoin and valued at about $8 million.&nbsp;With the $141.93 million second tranche, the combined investment totals approximately $150 million.&nbsp;Datavault said the investment will help it grow its digital asset reserves, expand supercomputing infrastructure, develop its platform, and create new revenue opportunities.&nbsp;<h2 class="st-heading-2">The Market Reaction</h2>Scilex Holding Company and Datavault partnered in September following Scilex’s $150 million investment. In addition to the capital infusion, Scilex secured a worldwide exclusive license reportedly valued at up to $10 million for Datavault’s AI and tokenization technology, focused on monetizing real-world assets and data, particularly in biotech and healthcare.<a href="https://stocktwits.com/symbol/SCLX">SCLX’s stock</a> dropped as much as 3.65% in pre-market trade despite strength in the broader market. On Stocktwits, it was among the top trending tickers. Data showed retail sentiment around the company rose to ‘extremely bullish’ from ‘bullish’ territory, accompanied by ‘high’ levels of chatter over the past day.&nbsp;<a href="https://stocktwits.com/symbol/DVLT">DVLT’s stock</a> edged 0.4% lower, with retail sentiment around the firm improving to ‘bullish’ from ‘neutral’ over the past day, with chatter at ‘high’ levels.<h2 class="st-heading-2">What Is Retail Thinking?</h2>One bullish user on Stocktwits said Scliex’s position in Datavault is now worth more than the original $150 million investment.&nbsp;<stembedurl>https://stocktwits.com/Sacsofcash/message/637487414</stembedurl>Another bullish trader anticipates ample runway ahead for the stock’s price to gain.<stembedurl>https://stocktwits.com/ToxicAvenger/message/637491996</stembedurl>SCLX’s stock has gained more than 30% this year, while DVLT’s stock has gained almost 10%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-xrp-ada-struggle-ahead-of-thanksgiving-analyst-warns-no-catalyst/cL53V2sREWP">Bitcoin, XRP, ADA Struggle Ahead Of Thanksgiving – Analyst Warns There’s No Clear Catalyst For Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of Bitcoin with stock market data. (Source: Andriy Onufriyenko/Getty Images)

Scilex Injects More Bitcoin Into Datavault AI, Unlocks 264M Share Warrant Issue

Retail sentiment on Stocktwits around both stocks rose over the past day, despite slight pre-market share price declines.

Equity

<ul class="summary-bullets"><li>Record shareholders of Scilex Holding Company will also be eligible for the meme coin airdrop.</li><li>Datavault AI described the decision as a gesture of appreciation for Scilex’s role as a stockholder, licensing partner, and co-sponsor of Dream Bowl XIV.</li><li>The board retains the right to alter the record date or revoke the airdrop before distribution based on solvency or surplus considerations.</li></ul>Datavault AI (DVLT) traded higher in pre-market hours on Monday after announcing that record shareholders as of today will qualify for its Dream Bowl 2026 meme coin airdrop set for January.<a href="https://stocktwits.com/symbol/DVLT/">DVLT’s stock</a> rose as much as 2.75% in pre-market trade. On Stocktwits, retail sentiment around the company dipped to ‘neutral’ from ‘bullish’ territory over the past day. To qualify for the distribution, holders must own Datavault AI shares as of the record date of November 25, 2025, the company said Friday.<h2 class="st-heading-2">Scilex Equity Holders Included in Airdrop Plan</h2>The company also said the airdrop will extend to record holders of Scilex Holding Company (SCLX) common stock. Datavault AI described the decision as a gesture of appreciation for Scilex’s role as a stockholder, licensing partner, and co-sponsor of Dream Bowl XIV, which is scheduled for January 11, 2026.<a href="https://stocktwits.com/symbol/SCLX">SCLX’s stock</a> rose as much as 18% in pre-market trade but later reversed, moving nearly 5% lower as the market open approached. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory, with chatter at ‘high’ levels.<h2 class="st-heading-2">Distribution Terms and Board Discretion</h2>Datavault AI said the Dream Bowl 2026 Meme Coins will be distributed to Data Vault wallets after the payment date, provided recipients elect to opt in, set up a digital wallet, and supply the required documentation.The company added that its Board of Directors may change the record date at any time before the payment date. The distribution remains subject to the Board’s approval and may be revoked, including in the event of a material change to the solvency or surplus analysis previously presented.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Datavault AI logo is seen displayed on a smartphone screen.

DVLT Shares Rise In Pre-Market On Upcoming Meme Coin Distribution For Record Shareholders

Record shareholders as of Monday will be eligible to receive the airdrop, scheduled for January.

Scilex (NASDAQ:SCLX) Posts Earnings Results, Misses Expectations By $21.76 EPS

Scilex (NASDAQ:SCLX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($22.17) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Scilex Holding Company (SCLX) on Thursday said that its majority-owned subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp (DECA) have entered into a purchase agreement with an investor for a $20 million private placement.The proceeds of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/10161/pdf">agreement</a> will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain. Lumbosacral radicular pain, often referred to as sciatica, is a pain that radiates along the sciatic nerve, which extends from the lower back down the leg.On Stocktwits, retail sentiment around Scilex remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. <a href="https://stocktwits.com/symbol/SCLX">SCLX stock</a> is trading 0.5% lower in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:567/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_7_24_17_AM_png_36aea133ff.webp" alt="SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="567" height="60"><figcaption>SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>Semnur and special purpose acquisition company (SPAC) Denali entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/9226/pdf">plan of merger</a> on Aug. 30, 2024, for a proposed business combination, among Semnur, the SPAC, and the SPAC's unit Denali Merger Sub Inc. This provided for a pre-transaction equity value of Semnur at $2.5 billion.&nbsp;Under the deal, the combined company will be renamed Semnur Pharmaceuticals, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol “SMNR”. The combination is now expected to close in September 2025.An investor has agreed to purchase an aggregate of 1.25 million shares of common stock of the combined company following the consummation of the merger transaction, Scilex said. The purchase price for the placement is $16.00 per share, for an aggregate purchase price of $20 million.The closing of the financing is subject to customary conditions and is expected to occur immediately following the consummation of the business combination, Scilex said.The company also said that CEO Jaisim Shah resigned as Scilex CEO and will now serve as chief executive and President of Semnur. Henry Ji, who currently serves as Executive Chairman of Scilex, was appointed as Scilex’s new CEO and President and has assumed all of the duties formerly performed by Shah, the company said.SCLX stock is up by 18% this year and down by 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/two-players-quietly-took-over-bitcoin-mining-power-heres-why-it-matters/chsSu9WRdi5">Two Players Quietly Took Over Bitcoin’s Mining Power — Here’s Why It Matters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.

Scilex Holding Co. (SCLX), a relatively under-the-radar player in the non-opioid pain management space, has unexpectedly captured the attention of retail investors. The company experienced a staggering 41.78% increase in retail followers on Stocktwits over the past month, despite a 21% decline in its share price.However, the initial bullish sentiment has waned, with Stocktwits sentiment flipping to bearish (36/100) and message volumes surging. This shift suggests growing investor skepticism amidst recent company developments.<figure class="image"><img style="aspect-ratio:1316/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SCLX_Sentiment_and_message_score_Aug_1_f79a43cdac.png" alt="SCLX Sentiment and message score Aug 1.png" width="1316" height="306"><figcaption>SCLX Sentiment and message score Aug 1</figcaption></figure>The surge in retail interest can be attributed to several factors. Primarily, the announcement of a potential $2 billion deal for its subsidiary, Semnur Pharmaceuticals, to go public through a SPAC merger with Denali Capital Acquisition Corp (DECA) has generated excitement. The proceeds from this deal are earmarked for the development of SP-102, a key drug candidate in late-stage trials.Additionally, Scilex had reported preliminary Q2 net sales above estimates, indicating revenue growth. However, a significant decline in cash and cash equivalents raised concerns.The company also entered into a collaboration agreement with ACEA for the potential expansion of its ZTlido treatment, used to help relieve nerve pain after shingles, in the Greater China region.While July saw continued sales growth for ZTlido, the pace of growth slowed compared to the previous month. This, coupled with the overall bearish sentiment and declining cash reserves, seems to have tempered initial enthusiasm.With Q2 earnings report scheduled for August 9th after market hours, investors will be closely watching for further clarity on the company's financial health and the progress of its key initiatives.Photo via Vecteezy

Small-Cap Scilex Drew Biggest Jump In Retail Following For July: What Drove It?

Retail investors flocked to Scilex, drawn by news about a lucrative SPAC deal for its unit, declining cash reserves and slowing sales growth.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

SCLX
Scilex Holding Company

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SCLX News

SCLXScilex Holding Company